Generic Name for TARGRETIN GEL
Bexarotene 1%; gel.
Legal Classification:
Rx
Pharmacological Class for TARGRETIN GEL
Retinoid.
Manufacturer of TARGRETIN GEL
Eisai Pharmaceuticals
Indications for TARGRETIN GEL
Cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
Adult dose for TARGRETIN GEL
Apply once every other day for the 1st week; then increase frequency at weekly intervals to once daily, then twice daily, then 3 times daily, then 4 times daily based on lesion tolerance. Usual dosing frequency: 2–4 times daily; may reduce if application site toxicity occurs. Allow gel to dry. Do not occlude.
Children's dosing for TARGRETIN GEL
Not recommended.
Contraindications for TARGRETIN GEL
Pregnancy (Cat.X).
Warnings/Precautions for TARGRETIN GEL
Be fully familiar with this drug's toxicity before use. Counsel patients monthly about need for contraception. Women of childbearing potential: obtain reliable negative pregnancy test within 1 week of start; repeat monthly. Start therapy on 2nd or 3rd day of normal menstrual period. Use two effective forms of contraception 1 month prior to, during, and for 1 month after therapy. Max 1 month/℞. Men with partners who are or may become pregnant: use condoms during and for at least 1 month after therapy. Hepatic or renal insufficiency. Discontinue temporarily if severe irritation occurs. Avoid sun, UV light, and mucosal membranes. Nursing mothers: not recommended.
Interactions for TARGRETIN GEL
Avoid concomitant products that contain DEET. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice). Caution with gemfibrozil. Limit Vit. A supplements to avoid toxicity.
Adverse Reactions for TARGRETIN GEL
Application site reactions (eg, rash, pruritus, skin disorders, pain, contact dermatitis).
How is TARGRETIN GEL supplied?
Gel—60g
Related Disease:
Lymphoma, cutaneous T-cell
DESCRIPTION
Targretin® (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for oral administration contains 75 mg of bexarotene.
The chemical name is 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl] benzoic acid, and the structural formula is as follows:
Bexarotene is an off-white to white powder with a molecular weight of 348.48 and a molecular formula of C24H28O2. It is insoluble in water and slightly soluble in vegetable oils and ethanol, USP.
通用名称为TARGRETIN凝胶
蓓萨罗丁1％;凝胶。
法律分类：
RX
TARGRETIN凝胶类药物
维甲酸。
TARGRETIN凝胶制造商
卫材制药
主治TARGRETIN凝胶
CTCL的（IA和IB期）其他疗法或谁后有难治性或持久性疾病患者的皮损不能耐受其他疗法。
成人剂量为TARGRETIN凝胶
申请隔日1周，然后在每周一班增加频率为每日一次，然后，每天两次，然后每日3次，然后每天4次，根据病变容忍。通常的给药频率：每日2-4次;可能会减少，如果申请地点毒性发生。允许凝胶晾干。不要阻挡。
儿童用药TARGRETIN凝胶
不推荐使用。
为TARGRETIN凝胶的禁忌
怀孕（Cat.X）。
警告/注意事项TARGRETIN凝胶
这种药物的毒性，使用前要充分熟悉。律师每月大约需要避孕的患者。育龄妇女：1开始的一周内获得可靠的妊娠试验阴性;重复每月。第2或第3天正常月经期开始治疗。使用避孕1个月有效形式之前，期间和治疗后1个月。最大1个月/℞。男子与合作伙伴，谁是或可能怀孕期间使用安全套和至少1个月的治疗后。肝或肾功能不全。如果发生严重的刺激，暂时中止。避免阳光，紫外线，和粘膜。哺乳母亲：不推荐。
TARGRETIN凝胶的相互作用
避免使用含有DEET的伴随产品。可能可以通过CYP3A4抑制剂（如酮康唑，伊曲康唑，红霉素，葡萄柚汁）。与吉非贝齐的注意事项。限制维生素。 A补充剂，以避免毒性。
TARGRETIN凝胶的不良反应
应用部位反应（如皮疹，瘙痒，皮肤疾病，疼痛，接触性皮炎）。
TARGRETIN凝胶是如何提供？
凝胶60G
相关疾病：
淋巴瘤，皮肤T细胞